Mar 12 |
ASLAN Pharmaceuticals announces $5M registered direct offering
|
Mar 12 |
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
|
Mar 12 |
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
|
Mar 11 |
ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
|
Mar 6 |
ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors
|
Feb 29 |
ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat
|
Jan 8 |
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
|
Jan 2 |
ASLAN Pharmaceuticals Announces Participation in January Investor Conferences
|
Dec 12 |
ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs
|
Nov 3 |
ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summit
|